Investment analysts at Guggenheim assumed coverage on shares of Longboard Pharmaceuticals (NASDAQ:LBPH) in a research report issued on Tuesday, Price Targets.com reports. The firm set a “buy” rating and a $27.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 77.17% from the company’s current price.
Separately, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell initiated coverage on Longboard Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $37.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, Longboard Pharmaceuticals has an average rating of “Buy” and a consensus target price of $32.75.
LBPH opened at $15.24 on Tuesday. Longboard Pharmaceuticals has a 52 week low of $15.24 and a 52 week high of $18.95.
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders.
Read More: Bull Market
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.